<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="522E0789-A5CA-4BC4-9734-E4C42FBF0339"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING"/>
	<title mediaType="text/x-hl7-title+xml">DIPHENHYDRAMINE HYDROCHLORIDE<br/>INJECTION, USP</title>
	<effectiveTime value="20060511"/>
	<setId root="522E0789-A5CA-4BC4-9734-E4C42FBF0339"/>
	<versionNumber value="1"/>
	<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>INTERNATIONAL MEDICATION SYSTEMS, LIMITED </name>
   </representedOrganization>
  </assignedEntity>
</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="936EFF2D-50EE-ECA3-6B6A-8D2A96D32513"/>
					<effectiveTime value="20060511"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0548-1390" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Diphenhydramine Hydrochloride</name>
								<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="50">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="50"/>
										</numerator>
										<denominator unit="mL" value="1">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="TC2D6JAD40" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Diphenhydramine Hydrochloride</name>
										<activeMoiety>
											<activeMoiety>
												<code code="8GTS82S83M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Diphenhydramine</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Diphenhydramine Hydrochloride </name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Hydrochloric Acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Sodium Hydroxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mL" value="1">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
										<asContent>
											<quantity>
												<numerator value="25">
													<translation code="C48540" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE" value="25"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0548-1390-00" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38291" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PARENTERAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section>
					<id root="DA907E64-73A7-EA92-BB4C-BDDBC0FA6249"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
					<text>
						<paragraph>Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. It occurs as a white, crystalline powder, is freely soluble in water and alcohol and has the molecular weight of 291.82. The molecular formula is C<sub>17</sub>H<sub>21</sub>NO&#8226;HCl. The structural formula is as follows:</paragraph>
						<renderMultiMedia referencedObject="MM1"/>
						<paragraph>Diphenhydramine hydrochloride injection is a sterile, pyrogen-free solution intended for I.M. or I.V. administration. Each mL contains 50 mg Diphenhydramine Hydrochloride, USP and sufficient hydrochloric acid and/or sodium hydroxide solution for pH adjustment (5.0&#8211;6.0). This product contains no antimicrobial preservative and is intended as a single use vial; once the unit is assembled and used, any remaining portion of the solution must be discarded with the entire unit.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
					<component>
						<observationMedia ID="MM1">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="diphenhydramine-image01.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="5666D002-E0FD-7B2A-24B7-8FDC176E83BE"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
					<text>
						<paragraph>Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.</paragraph>
						<paragraph>Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
				</section>
			</component>
			<component>
				<section>
					<id root="6F427694-9CAD-AD6F-9913-F63B82D3DD3B"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
					<text>
						<paragraph>Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when Diphenhydramine in the oral form is impractical.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
					<component>
						<section>
							<id root="0CA3AA65-FF6D-DC2C-1094-47D5A4EC0AE1"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Antihistaminic</title>
							<text>
								<paragraph>For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="C3AF9825-AB59-493A-CC69-765814B37F9A"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Motion Sickness</title>
							<text>
								<paragraph>For active treatment of motion sickness.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="A5593ACD-472C-821B-D646-3C2D84B5A235"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Antiparkinsonism</title>
							<text>
								<paragraph>For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents, mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Contraindications">
					<id root="AED5FA0B-186F-3726-3A2A-1FAEC6705DCE"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
					<effectiveTime value="20060511"/>
					<component>
						<section>
							<id root="2674C668-9A85-CC78-960D-B185D1A3F35C"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Use in Neonates or Premature infants</title>
							<text>
								<paragraph>This drug should <content styleCode="Bold Italics">not</content> be used in neonates or premature infants.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="122FB6B7-0B97-F019-04BE-1293FFBFD99A"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Use in Nursing Mothers</title>
							<text>
								<paragraph>Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="8D7BAD60-CA07-A89A-76EB-511030818931"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Use as a Local Anesthetic</title>
							<text>
								<paragraph>Because of the risk of local necrosis, this drug should not be used as a local anesthetic.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="F8C17E10-6B43-E6C0-089A-1EE67F41B7AA"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Antihistamines are also contraindicated in the following conditions</title>
							<text>
								<paragraph>Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Warnings">
					<id root="B1A293B3-BF1D-69BF-F6C6-D8170E9708E6"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
					<text>
						<paragraph>Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.</paragraph>
						<paragraph>Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
					<component>
						<section>
							<id root="F7837046-D518-12B8-3513-53F553628371"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Use in Pediatric Patients</title>
							<text>
								<paragraph>In pediatric patients, especially, antihistamines in <content styleCode="bold italics">overdosage</content> may cause hallucinations, convulsions, or death.</paragraph>
								<paragraph>As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="24572FE9-23E3-AD6E-3D21-0B98987F7857"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Use in the Elderly (approximately 60 years or older)</title>
							<text>
								<paragraph>Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="EB38C6E4-3C7B-CA5A-E46E-FB446821FB52"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
					<effectiveTime value="20060511"/>
					<component>
						<section>
							<id root="8ED4A660-508E-66C3-159D-2E4D737872E6"/>
							<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">General</title>
							<text>
								<paragraph>Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease, including asthma.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="9338F1D2-E354-F979-60E4-756254AB253A"/>
							<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INFORMATION FOR PATIENTS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
							<text>
								<paragraph>Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.</paragraph>
								<paragraph>Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="8E8336E6-5DA8-6B18-E1A9-3861C4B67ACC"/>
							<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
							<text>
								<paragraph>Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).</paragraph>
								<paragraph>MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="B8230177-CF5A-F4AE-58DC-458D18ED3189"/>
							<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
							<text>
								<paragraph>Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="52630BD4-E08B-5947-FEE7-C26D84497934"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY"/>
							<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
							<effectiveTime value="20060511"/>
							<component>
								<section>
									<id root="3B5C8497-2509-8A69-4CCB-B8D182626488"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">Pregnancy Category B</title>
									<text>
										<paragraph>Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose an have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
									</text>
									<effectiveTime value="20060511"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="3BBF114E-7238-A801-0EAF-584CD234F95D"/>
							<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
							<text>
								<paragraph>Diphenhydramine Hydrochloride Injection should not be used in neonates and premature infants (see <linkHtml href="#Contraindications">CONTRAINDICATIONS</linkHtml>).</paragraph>
								<paragraph>Diphenhydramine Hydrochloride Injection may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see <linkHtml href="#Warnings">WARNINGS</linkHtml> and <linkHtml href="#Overdosage">OVERDOSAGE</linkHtml>). See also <linkHtml href="#Dosage_Administration">DOSAGE AND ADMINISTRATION</linkHtml> section.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="F8112A25-F762-EE96-122B-F3AD2C4C8349"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
					<text>
						<paragraph>
							<content styleCode="bold">The most frequent adverse reactions are underscored.</content>
						</paragraph>
						<list listType="ordered">
							<item>
								<content styleCode="italics">General</content>: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose, and throat</item>
							<item>
								<content styleCode="italics">Cardiovascular System</content>: Hypotension, headache, palpitations, tachycardia, extrasystoles</item>
							<item>
								<content styleCode="italics">Hematologic</content>: Hemolytic anemia, thrombocytopenia, agranulocytosis</item>
							<item>
								<content styleCode="italics">Nervous System: </content>
								<content styleCode="underline">Sedation sleepiness, dizziness, disturbed coordination,</content> fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions</item>
							<item>
								<content styleCode="italics">GI System</content>: <content styleCode="underline">Epigastric distress,</content> anorexia, nausea, vomiting, diarrhea, constipation</item>
							<item>
								<content styleCode="italics">GU System</content>: Urinary frequency, difficult urination, urinary retention, early menses</item>
							<item>
								<content styleCode="italics">Respiratory System</content>: <content styleCode="underline">Thickening of bronchial secretions,</content> tightness of chest or throat and wheezing, nasal stuffiness.</item>
						</list>
					</text>
					<effectiveTime value="20060511"/>
				</section>
			</component>
			<component>
				<section ID="Overdosage">
					<id root="74DB2A39-3534-CED2-B257-F57260602491"/>
					<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
					<text>
						<paragraph>Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing and gastrointestinal symptoms may also occur.</paragraph>
						<paragraph>
							<content styleCode="bold italics">Stimulants</content> should not be used.</paragraph>
						<paragraph>Vasopressors may be used to treat hypotension.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
				</section>
			</component>
			<component>
				<section ID="Dosage_Administration">
					<id root="98E825E7-1821-FB42-CB31-B2E7BE906C65"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
					<text>
						<paragraph>THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.</paragraph>
						<paragraph>Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical.</paragraph>
						<paragraph>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</paragraph>
					</text>
					<effectiveTime value="20060511"/>
					<component>
						<section>
							<id root="9854C808-E0F2-9982-E51C-2639C1950BE3"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Patients</title>
							<text>
								<paragraph>
									<content styleCode="bold">Other than premature infants and neonates:</content> 5 mg/kg/24 hr or 150 mg/m<sup>2</sup>/24 hr. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
					<component>
						<section>
							<id root="8F379249-9F87-C2D2-106C-64437E87C2E5"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Adults</title>
							<text>
								<paragraph>10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly; 100 mg if required; maximum daily dosage is 400 mg.</paragraph>
								<paragraph>
									<content styleCode="bold">NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</content>
								</paragraph>
							</text>
							<effectiveTime value="20060511"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="6EBF605C-4B5A-52F1-1899-3FEE20B0E0DB"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
					<text>
						<paragraph>Diphenhydramine Hydrochloride Injection, USP, 50 mg per mL, 1 mL vial.<br/>In unit-use packages containing one single dose vial and a vial injector.<br/>Twenty-five unit-use packages per carton.</paragraph>
						<paragraph>Stock No. 1390&#160;&#160;&#160;&#160;&#160;&#160;NDC 0548-1390-00&#160;&#160;&#160;&#160;&#160;&#160;1 mL&#160;&#160;&#160;&#160;&#160;&#160;21 G. &#215; 1 1/2" Needle</paragraph>
					</text>
					<effectiveTime value="20060511"/>
				</section>
			</component>
			<component>
				<section>
					<id root="3F58914E-B438-D956-DB9C-342C2C7389C2"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">Syringe Assembly Directions</title>
					<text>
						<paragraph>
							<content styleCode="Bold">USE ASEPTIC TECHNIQUE</content>
						</paragraph>
						<paragraph>
							<content styleCode="Bold">Do not assemble until ready to use.</content>
						</paragraph>
						<renderMultiMedia referencedObject="MM2"/>
						<paragraph>*CAUTION: IMPROPER ENGAGING MAY CAUSE GLASS BREAKAGE AND SUBSEQUENT INJURY.</paragraph>
						<paragraph>
							<content styleCode="bold">Store at Controlled room temperature 15&#176; to 30&#176;C (59&#176; to 86&#176;F). Protect from light. Retain in carton until time of use.</content>
						</paragraph>
					</text>
					<effectiveTime value="20060511"/>
					<component>
						<observationMedia ID="MM2">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="diphenhydramine-image02.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="7897C427-84C3-17E3-9512-881FAADAA71D"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml"/>
					<text>
						<paragraph>
							<content styleCode="bold">Rx Only</content>
						</paragraph>
						<paragraph>
							<content styleCode="bold">INTERNATIONAL MEDICATION SYSTEMS, LIMITED </content>
						</paragraph>
						<paragraph>So. El Monte, CA 91733, U.S.A.<br/>Amphastar Pharmaceuticals Company</paragraph>
						<paragraph>
							<content styleCode="bold">Rev.7-00</content>
						</paragraph>
						<paragraph>6913900J</paragraph>
					</text>
					<effectiveTime value="20060511"/>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
